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Key messages 
What is already known about this subject? 
Pain is the main problem reported by people with active RA, and systemic 
glucocorticosteroids are recommended for treatment, but the magnitude and duration 
of their effects on pain is not known. 
 
What does this study add? 
Systemic glucocorticosteroids were most effective for pain during the first 3 months 
of treatment, with treatments of longer than 6 months showing low efficacy. 
Future research should address which individuals will most benefit from the anti-
inflammatory effects of systemic glucocorticosteroids. 
 
How might this impact on clinical practice or future developments? 
Systemic glucocorticosteroid treatments provided for pain should be time-limited. 
New treatments are required to improve pain in people with RA.
Abstract 
Background. Glucocorticosteroids (GCs) are recommended to suppress 
inflammation in people with active RA. This systematic review and meta-analysis 
aimed to quantify the effects of systemic GCs on RA pain. 
Methods. A systematic literature review of randomised controlled trials (RCTs) in RA 
comparing systemic GCs to inactive treatment. Three databases were and 
spontaneous pain and evoked pain outcomes were extracted. Standardized mean 
differences (SMDs) and mean differences (MDs) were meta-analysed. Heterogeneity 
(I², tau statistics) and bias (funnel plot, Eggers test) were assessed. Subgroup 
analyses investigated sources of variation. This study was pre-registered 
(PROSPERO CRD42019111562).  
Results. 18903 titles, 880 abstracts and 226 full texts were assessed. Thirty three 
RCTs suitable for the meta-analysis included 2658 participants.  
Pain scores (spontaneous pain) decreased in participants treated with oral GCs; 
SMD= -0.65 (15 studies, 95% CI, -0.82, -0.49, p<0.001) with significant 
heterogeneity (I²=56%, p=0.0002). Efficacy displayed time-related decreases after 
GC initiation. Mean difference VAS pain was -12mm (95% CI, -14mm to -9mm) 
greater improvement in GC than control at ≤3 months, -8mm (95% CI, -12mm, -
3mm) at >3 to 6 months, and -6mm (95% CI, -10mm, -2mm) at >6 months. Similar 
findings were obtained when evoked pain outcomes were examined. Data from 5 
RCTs suggested improvement also in fatigue during GC treatment. 
Discussion. Oral GCs are analgesic in RA. The benefit is greatest shortly after 
initiation and GCs might not achieve clinically important pain relief beyond 3 months.  
Treatments other than anti-inflammatory GCs should be considered to reduce the 
long-term burden of pain in RA. 
Keywords: rheumatoid arthritis, glucocorticoids, pain, tender joint, meta-analysis  
Introduction  
Pain is the most troublesome symptom of RA (1). Glucocorticosteroids (GCs) are 
used to provide rapid relief of symptoms in people with active RA, as part of disease-
modifying combination treatments (2, 3). Current clinical practice uses GCs with a 
range of doses, treatment durations and routes of administration. Short-term, low 
dose oral GCs are effective in reducing pain (4, 5), but the magnitude and duration of 
benefit over placebo are uncertain for the range of regimens in current clinical 
practice. Long-term GC use is associated with significant health problems, such as 
total joint replacement, osteoporosis, diabetes mellitus and cardiovascular risk (6, 7). 
A precise understanding of benefit is required to inform decisions about their use to 
relieve pain.  
Persistent pain remains a problem in RA. Disease modifying anti-rheumatic drugs 
(DMARDs), including biologics, reduce pain from the high levels associated with high 
disease activity. However, complete pain resolution is not common and there may be 
multiple mechanisms acting on the pain experience. Many people report persistent 
pain despite inflammation responding well to biologic treatment (8). People with RA 
experience pain at rest and during normal activities. They also display increased 
sensitivity to evoked pain, in response to stimuli such as normal movement or gentle 
pressure on the joints. This pain sensitivity may indicate sensitisation of peripheral or 
central nociceptive pathways and contributes to the clinical pain reported by people 
with RA (9). Peripheral sensitisation may be due to articular inflammation. In 
addition, widespread pain and other evidence of central sensitisation are common 
and contribute to pain in people with RA (10). Chronic pain is strongly associated 
with fatigue, which may itself be an indication of central sensitisation (11, 12). 
Chronic joint pain in longstanding, inadequately controlled disease, might in addition 
be influenced by common secondary osteoarthritis (13). Systemic GCs and 
DMARDs might therefore not be sufficient to adequately relieve pain in people with 
RA. 
To inform the optimal use of systemic GCs, this study aimed to quantify the specific 
effects of systemic GCs for pain in people with RA, including both clinical and 
evoked pain (joint tenderness), across treatment durations, routes of administration 




OVID Medline, OVID Embase and Cochrane CENTRAL databases were searched 
for studies until 22nd October 2020. Reference lists of publications were also 
searched. Search terms are presented in Supplement 1. Reviewers independently 
assessed titles, abstracts and full texts in duplicate (DMc with JJ-D, DT, RM, OSI). 
No language restrictions were placed on searching, but only data that were reported 
in English language were extracted. Study selection is summarised in Figure 1. Data 
extraction was performed in duplicate using a pre-designed form (DMc, JJD, DT, 
OSI). Any disagreements were resolved through discussion and if necessary, the 
involvement of another author (DAW). 
The following study characteristics were extracted. Descriptives. First author, year of 
publication, name of trial, registration number of trial. Participants and clinical details 
at baseline. Number, age data, sex data, disease activity score (DAS), 28-joint DAS 
(DAS28), Health Assessment Questionnaire (HAQ), and other indicators of RA 
activity/severity. Interventions. GC and disease modifying anti-rheumatic drug 
(DMARD) name(s), GC dose(s), sample size (n) per trial arm, route of GC 
administration, duration of GC administration, duration of follow up assessments. 
Outcomes. All pain-related outcomes including fatigue outcomes at all time points 
reported. Data were extracted from published graphs using manual measurement. 
Crossover trial data from all phases of the study were used (14) Trial quality and risk 
of bias indicators were recorded as high/low risk of bias or unclear (14). Random 
sequence generation, allocation concealment, blinding of participants, blinding of trial 
physicians, blinding of outcome observers, study attrition rate (>15% threshold 
used), intention to treat (ITT) analysis, outcome reporting. Trial reports that scored 
≥4 low risk items were classified as high quality for the purposes of this study. 
 
 
Types of studies and participants 
Randomised controlled trials (RCTs) published in the peer-reviewed literature were 
included.  Studies were in adults (≥18 years) diagnosed with RA by a physician or 
formally classified according to published criteria (eg. (15)). .  
Types of interventions 
Studies were included if they allowed systemic GCs to be compared to an inactive 
treatment (with other DMARDs kept equal or stable across the study arms), or 
comparisons between different GC treatments or regimens (eg. dosages or routes of 
administration). Studies were included when participants received other DMARD 
treatments, so long as a specific treatment effect could be assigned to systemic 
GCs. One synthetic agonist of the GC receptor was also identified during the 
searches and was included. 
Studies of intraarticular GC administration were excluded. 
Types of outcome measures 
Pain outcomes were classified as `spontaneous‘ or `evoked‘. Spontaneous pain 
included bodily pain, joint pain, or morning/evening pain. Evoked pain included 
observer-induced pain measured by Ritchie Articular Index, tender joint counts, and 
quantitative sensory testing/measures of pain sensitivity also pain reported upon 
movement. All pain outcomes from all time points were recorded. Additional to the 
published protocol, a parallel synthesis of fatigue, as a pain-related outcome 
measure, was performed and all fatigue measures were extracted. Painful adverse 
effects/events were not extracted or analysed. 
Measures of treatment effect 
The average outcome measure and an estimate of its spread/variation were 
extracted. If no other data were available, then published median and IQR were used 
to estimate the mean and sd (1.35xIQR (14)). Each study‘s own published data were 
used to extrapolate missing sds and other values (using RevMan5 software 
calculator, Cochrane collaboration). Mean (sd) values were calculated for short 
ordinal scales, such as pain score from 0-3, by treating the scales like continuous 
data. Unless stated otherwise, the first reported follow up time point per study was 
used for analysis.  
Statistical analysis and meta-analysis 
Meta-analyses of pain, evoked pain and fatigue were performed in parallel. 
Standardized mean differences (SMDs) were calculated for follow-up time points (the 
primary dependent variable for this study) and for change scores from baseline 
(mean and sd of change from baseline). Mean differences (MDs) of each measure 
were also calculated, allowing estimation of the absolute patient-reported levels of 
improvement, rather than standardised measures of relative effects. As tender joint 
count (TJC) and Ritchie Articular Index (RAI) are both indices of tender joints, their 
scores were normalised allowing for MD to be calculated for studies using either 
score. Meta-analyses were performed using the Meta (16, 17) and Metafor (18) 
packages in R, weighted by standard inverse-variance methods ((14)). 
Heterogeneity was quantified using I² and tau statistics (19) and the p value of the Q 
statistic, p(Q) (19) . Bias was assessed with a funnel plot and Eggers test (20). 
Subgroup analyses were performed to investigate potential sources of variation; 
administration route, duration of treatment and risk of bias. 
Metaregression analysis for pain data from all time points of each study was used to 
look for the association between duration of follow up (or improvement in 
inflammation) and the SMD and was adjusted for multiple observations within 
studies. Metaregressions were performed using multilevel analyses with level 3 = 
study, level 2 = participant, level 1= outcome data from all reported time points (21).  
Results 
Study selection and systematic review 
18903 papers were identified, 880 abstracts were selected for review and 226 full 
texts were assessed. A total of 65 full texts were retrieved, of which 34 reported GC 
efficacy for spontaneous pain, 38 for evoked pain and 26 additional texts reporting 
other comparisons related to pain (some recorded multiple outcomes, Table 1). The 
study selection process is summarised in Figure 1. The systematic review of GC 
efficacy for pain in RA is summarised in the harvest plot in figure 2. None of the 
studies reported increased pain outcomes in response to systemic GC treatment, 
and most studies reported a significant improvement during follow up (figure 
2A,D,G). Details of the studies comparing GC with inactive comparator are shown in 
Table 1 (for those included in meta-analysis) and Supplement 2 (all studies).  
A total of 33 studies (27 for spontaneous pain and 24 for evoked pain measures) 
were included for the meta-analyses. Most of these studies reported oral GC dosing 
(n=23); whereas 4 studies used intramuscular, 5 studies used intravenous and 1 
study used iontophoresis routes of administration. Commonest measures reported 
were the 100mm pain visual analogue scale (VAS; n=26), 28 joint tender joint count 
(TJC; n=22) and Ritchie Articular Index (RAI; n=13)). A total of 2658 participants 
(68% female) were enrolled in the 33 studies. Mean age of participants was 54 
years. Baseline disease activity characteristics indicated active RA (Supplement 2). 
Spontaneous pain 
Meta-analysis of spontaneous pain data from all studies at the single earliest 
available time point (n=22 studies) showed SMD (95% CI) for GCs on spontaneous 
pain of -0.67 (-0.84 to -0.50) with significant heterogeneity measured by I² = 62%, tau 
= 0.28, p(Q) <0.01 (Eggers p value for asymmetry <0.0001). Oral GCs were 
examined alone (n=15 studies) and showed a statistically significant reduction in 
spontaneous pain (figure 3A for forest plot and figure 3B for funnel plot) with SMD = -
0.65 (-0.82 to -0.49) with significant heterogeneity (I² = 56%, tau = 0.21, 
p(Q)=0.0045). The Funnel plot indicated statistically significant asymmetry for the 
analyses of oral GCs (Eggers p <0.0001, Figure 3B). Mean Differences for a VAS 
pain showed improvements of -11mm (-15 to -7 mm) with significant heterogeneity 
(I² = 62%, tau = 4.7, p(Q)=0.0024). Eggers test for funnel plot asymmetry yielded p = 
0.052. 
Further subgroup analyses investigated the time course of oral GCs effects on 
spontaneous pain. Efficacy displayed time-related decreases across 3 subgroups of 
increasing duration (figure 4A). For these studies, the MDs in 100mm VAS pain 
showed the greatest improvement (-12mm) in the 0-3 month period (figure 4B), with 
MDs of -8mm and -7mm for longer durations of treatment (>3 months to 6 months; 
and >6 months respectively). These findings were supported by the SMD and MD for 
change in spontaneous pain (Supplement 3) and by metaregression (Supplement 4).  
Trials classified as high quality retained similar findings to those from all studies. The 
earliest time point for all high quality trials showed 14 studies with SMD =-0.57 (95% 
CI -0.73 to -0.342. Time-related changes in efficacy of oral GCs in high quality 
studies are shown in Supplement 5A.  
No association was detected between routes of administration and analgesic effect 
(Supplement 6). Meta-regression analysis indicated that improvements in ESR were 
associated with improvements in spontaneous pain (Supplement 7). 
Evoked pain 
A meta-analysis of evoked pain from all studies at the single earliest available time 
point (n=29) showed SMD (95%CI) for GCs of -0.57 (-0.75 to -0.41) with significant 
heterogeneity I² = 68%, tau = 0.37, p(Q) <0.001 (Eggers p = 0.0048). Oral GCs 
(n=15 studies) showed a statistically significant reduction in evoked pain of -0.71 (-
0.97 to -0.45) with heterogeneity I² = 78%, tau = 0.43, p(Q) <0.001 (Eggers p = 
0.0003). In oral GCs, the MD for a harmonised TJC and RAI joint scores showed 
improvements equivalent to 2.5 tender joints or 9.7 points of the RAI (normalised MD 
= -0.12 (-0.18 to -0.07), with tau = 0.09, I² = 79%, p(Q)<0.001 (Eggers p=0.0008). 
Subgroup analysis was used to investigate the time course of oral GCs on evoked 
pain. A pattern of decreasing efficacy at the >6 months subgroup was observed 
(Figure 5). The MDs for a normalised TJC and RAI joint score showed improvements 
that decreased as follow up time progressed; equivalent to 3.6 tender joints or 10 
points of RAI for the first 3 months and decreasing to 0.8 joints or 2.3 points on the 
RAI in the >6 month treatment duration category (Supplement 8). 
Trials classified as high quality retained similar findings to the overall comparisons. 
The earliest time point for all higher quality GC reports showed n=16 studies with 
SMD -0.52 (-0.73 to -0.31). Time-related changes in efficacy of oral GCs in higher 
quality studies are shown in Supplement 5B.  
Different routes of GC administration derived evoked pain SMD (95% CI) for each 
route as oral -0.71 (-0.97 to -0.45, n=15 studies), intramuscular -0.08 (-0.53 to 0.35, 
3 studies) and intravenous -0.33 (-0.76 to 0.10, n=6 studies) administration 
(heterogeneity between subgroups p=0.069). 
GC withdrawal studies and head-to-head comparisons between GCs or 
treatment regimens. 
The studies related to GC withdrawal and head-to-head comparisons of GCs are 
shown in Supplement 9.  Both spontaneous and evoked pain worsened with GC 
withdrawal in most studies (Figure 2). Higher doses of GC were generally not 
associated with greater pain improvement (Figure 2). Head-to-head comparisons of 
different oral GCs found that 1mg betamethasone and 8mg prednisolone daily gave 
similar outcomes (22), as did budesonide at 9mg and 3mg daily (23). One trial of the 
GC receptor partial agonist Fosdagrocarat daily at 15mg gave similar outcomes to 
10mg prednisolone but stronger response for spontaneous pain than 5mg 
prednisolone after 8 weeks (24). Another study of Fosdagrocarat found similar 
responses for 25mg and 10mg of the agonist compared to 7.5mg and 5mg 
prednisolone (25).  
Aqueous drops and tablets of deflazacort were found to give similar outcomes over 3 
weeks (26). Intramuscular methylprednisolone (120mg every 4 weeks) improved 
spontaneous pain more than 500mg tablets (every 4 weeks) but evoked pain 
changes were similar between groups(27). Intravenous methylprednisolone (1000mg 
for 3 days) and oral tablets (1000mg for 3 days) gave similar levels of pain 
improvement (28). 
Delayed release prednisolone gave similar pain improvement to standard release 
after 12 weeks of night-time dosing in the CAPRA-1 study (29). Six weeks of 
ultradian dosing gave similar results to circadian dosing of prednisolone in one trial 
(30). Additionally, dosing at 2am with 7.5mg prednisolone yielded greater pain 
improvements than 7.30am doses (25mm difference on 100mm VAS) in one study 
(31). 
Fatigue 
Five studies reported fatigue outcomes in response to systemic GCs (32-37). 
Fatigue was reported to improve with GC use in three trials verses placebo (2 high 
quality double-blind studies (33, 36) and 1 open-label(37)); using fatigue scales of 
FACIT-F, VAS and SF36-Vitality. These studies contained a total of 907 people that 
used oral GCs between 12 to 28 weeks. A meta-analysis of fatigue suggested GC 
was associated with an SMD (95% CI) of -0.24 (-0.47 to 0.00, 3 studies) when 
compared to placebo(33, 36, 37). Withdrawal of oral GCs (and replacement with 
placebo) was reported to increase fatigue in two trials (34, 35). 
 
Discussion 
The data suggests that systemic GCs reduce pain outcomes in people with active 
RA. Heterogeneity between studies was partly explained by duration of GC 
treatment, but not by route of administration nor study quality. Systemic GCs may 
also improve fatigue in people with active RA. Pain improvement with systemic GCs 
was most pronounced within 3 months of starting treatment, and might be 
substantially less beyond 6 months.  
Systemic GCs are often administered to provide symptomatic relief for people with 
active RA. Current UK treatment guidelines recommend GC use in early RA, for 
bridging and for flares (2) and examples of all these were included in our meta-
analysis. Long term GC use is recommended if other DMARDs have been 
unsuccessful (2). At an individual level, improvements of 10-20mm on a 100mm VAS 
pain scale may be considered clinically important (38). Mean effects beyond the first 
6 months of treatment might not be clinically important, suggesting that fewer than 
half of participants on long term GC treatment gain a clinically important 
improvement above placebo responses. Systemic GCs also reduced fatigue, but 
again improvements were small by comparison with placebo. Lack of analgesic dose 
response for oral GCs, or between oral and parenteral GCs might suggest that 
maximum analgesic effect is achieved with low doses of oral prednisolone (possibly 
≤15mg daily). Long term GC use, particularly at high doses, is associated with risk of 
adverse events, including total joint replacement, fracture risk, diabetes melitus and 
cardiovascular disease(7, 39). Systemic GCs are effective for reducing pain in 
people with active RA, but benefits might not outweigh risks with long term 
treatment. 
We categorised pain outcomes as spontaneous or evoked. We found similar 
magnitudes of reductions in both spontaneous and evoked pain outcomes with 
systemic GCs, supporting the relevance of evoked pain to clinically important pain 
for the person with RA. Fatigue reflects mechanisms within the central nervous 
system closely associated with central sensitisation and pain and is also an 
important outcome for people with RA (12, 40). Systemically administered GCs cross 
the blood brain barrier and may have psychoactive effects (some of which may be 
undesirable) (41). However, the analgesic response to GCs is more likely to be due 
to anti-inflammatory effects within joints, rather than actions on the central nervous 
system. The relatively weak response of fatigue to GC treatment also implies that 
central mechanisms might not be much altered. Long term analgesic benefit from 
systemic GCs might be suggested by increased pain during withdrawal, but it is 
possible that steroid-responsive individuals are enriched in these trials. Pain is 
exacerbated by stress (42), and steroid withdrawal might be associated with 
physiological changes which could increase pain, particularly in long-term users. 
This study has several limitations. Not all studies reported pain outcomes, despite 
pain being common and a VAS being part of the ACR20 (43), and not all reported 
data were amenable to meta-analysis. However, the findings from meta-analysis 
were corroborated by the other studies that were included in our systematic review. 
Different treatment regimens, such as bridging and combination therapies, were 
used in different studies, although all studies allowed for specific GC effects to be 
assigned. Studies using GCs as part of a combination, but without suitable controls 
for our study, were not included. Aspects of quality of life other than pain and fatigue 
are important to patients, but were not addressed by our study. Systemic GCs may 
be used as a disease modifying agent (3, 4). Effects on pain may differ according to 
whether pain was the primary indication for GC use. The reliance upon self-report is 
a necessary limitation in studies of pain, which is, by definition, a subjective 
experience. Although most included studies measured contemporaneous reporting 
of pain, there may be heterogeneity in self-reporting across time, for multiple reasons 
such as memories or previous experiences of pain influencing future reporting, or 
variability of the metric. Many trials were small and focussed on short treatment 
durations. Additional studies, beyond 6 months, could provide more accurate 
estimates of analgesic efficacy.  
The current use of GCs to treat RA pain appears to be largely guided by clinical 
experience rather than robust evidence from randomised controlled trials. Many 
patients receive GCs, often at high dose, when DMARDs have not controlled pain, 
and estimates from the USA suggested that up to one third of people with RA might 
be using regular systemic GCs (6). The benefit from systemic GCs appears to 
diminish with time while risks of adverse events may increase. The studies we 
retrieved of head-to-head GC comparisons did not provide a consensus regarding 
the effects of different regimens (44), as the different studies were heterogeneous 
and might not reflect current clinical practice. Further research is needed to 
determine who could benefit most from systemic GCs to inform personalised 
treatment. More research is also required to determine the potential benefits and 
risks of withdrawal in people who are already using long term systemic GCs. The 
evidence from this review suggests systemic GCs are not a complete solution to RA 
pain and additional analgesic strategies are urgently needed. 
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Figure 1: Flow diagram of searches and study selection  
 
 
Flow diagram showing the search and selection strategy of studies. Studies may contribute to more 
than one outcome. 
 
 







This harvest plot summarises all of the different types of evidence for the primary hypothesis in the systematic review of glucocorticosteroid 
(GC) efficacy for pain outcomes. Each study can provide spontaneous and evoked pain data, which are represented as single bars (each study 
can contribute a spontaneous and an evoked pain outcome to each row of three panels, eg. Panels A,B,C). The height of each bar is the study 
quality (range 0 to 9). Study results that showed statistically significant evidence for GCs improving pain are shown in the left hand panels (A, 
D, G, M); studies that only found non-significant differences are shown in the middle panels (B, E, H, K, N). No studies reported that GCs 
increased pain (right hand panels C, F, I, L, O). Panels A, B, C summarise all trials of GC vs inactive comparator (all analysis methodologies). 
Panels D, E, F summarise all data comparing GC vs inactive comparator (the primary method for calculating SMDs and MD in this review; 
these are subsets of panels A,B,C). Panels G, H, I summarise all data comparing change scores for pain between GC and inactive comparator 
(the secondary method of calculating SMDs in this review; these are subsets of panels A,B,C). Panels J, K, L summarise data from trials that 
withdrew GCs and replaced them with placebo (increased pain implied that GCs were effective at reducing pain prior to withdrawal). Panels M, 
N, O summarise dose-response studies (higher doses of GCs reduce pain more than lower doses). If any reported significant difference in pain 
was reported, the study is presented as showing a significant difference. 
 
 
Table 1: Studies included in primary meta-analyses of pain and evoked pain. 
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Description of studies included in meta-analysis 
 
Figure 3: Earliest time point and pain in response to oral glucocorticosteroids 
A). Forest plot: Earliest time point in trials of oral glucocorticosteroids.  
 
 
B). Funnel plot: Earliest time point in trials of oral glucocorticosteroids  
 
A – Standardised mean differences of pain in trials of oral glucocorticosteroids (GCs). Forest plot showing results of random effects meta-analysis. Negative 
values favour GC over comparator. B – Funnel plot of effect sizes. Eggers test p <0.0001. 
 
Figure 4: Forest plot for subgroup analysis of pain stratified by duration of treatment with oral glucocorticosteroids 






A. Standardised mean differences of pain in trials of oral glucocorticosteroids (GCs), and B mean differences of 100mm VASpain stratified by duration of follow up. 








Standardised mean differences of evoked pain in trials of oral glucocorticosteroids (GCs), stratified by duration of follow up Tender joints, Ritchie Aritcular Index and pain 
upon movement were included. Forest plot showing results of random effects meta-analysis. Negative values favour GC over comparator.  Each trial may contribute data to 
each of the 3 follow up time periods. 
References 
 
1. Taylor P, Manger B, Alvaro-Gracia J, Johnstone R, Gomez-Reino J, Eberhardt E, et al. Patient 
perceptions concerning pain management in the treatment of rheumatoid arthritis. J Int Med Res. 
2010;38(4):1213-24. 
2. NICE. NG100: Rheumatoid arthritis in adults: management 2020 [Available from: 
https://www.nice.org.uk/guidance/NG100. 
3. Kirwan J, Bijlsma JWJ, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression 
in rheumatoid arthritis. Cochrane Database Syst Rev. 2007;1:CD006356. 
4. Kirwan J. The origins, results and consequences of the 1995 Arthritis Research Campaign 
Low-Dose Glucocorticoid Study. Clin Exp Rheumatol. 2011;29(5 Suppl 68):S52-8. 
5. Gøtzsche PC, Johansen HK, Group CM. Short‐term low‐dose corticosteroids vs placebo and 
nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev. 
2005;1:CD000189. 
6. Caplan L, Wolfe F, Russell AS, Michaud K. Corticosteroid use in rheumatoid arthritis: 
prevalence, predictors, correlates, and outcomes. J Rheumatol. 2007;34(4):696-705. 
7. Hua C, Buttgereit F, Combe B. Glucocorticoids in rheumatoid arthritis: current status and 
future studies. RMD Open. 2020;6(1). 
8. McWilliams DF, Walsh DA. Factors predicting pain and early discontinuation of tumour 
necrosis factor-alpha-inhibitors in people with rheumatoid arthritis: results from the British society 
for rheumatology biologics register. BMC Musculoskelet Disord. 2016;17:337. 
9. Joharatnam N, McWilliams DF, Wilson D, Wheeler M, Pande I, Walsh DA. A cross-sectional 
study of pain sensitivity, disease-activity assessment, mental health, and fibromyalgia status in 
rheumatoid arthritis. Arthritis Res Ther. 2015;17:11. 
10. Heisler AC, Song J, Dunlop DD, Wohlfahrt A, Bingham CO, III, Bolster MB, et al. Association of 
Pain Centralization and Patient-Reported Pain in Active Rheumatoid Arthritis. Arthritis Care Res 
(Hoboken). 2020;72(8):1122-9. 
11. Strand V, Kaine J, Alten R, Wallenstein G, Diehl A, Shi H, et al. Associations between Patient 
Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc 
analysis of data from phase 3 trials of tofacitinib. Arthritis Res Ther. 2020;22(1):243. 
12. Druce KL, McBeth J. Central sensitization predicts greater fatigue independently of 
musculoskeletal pain. Rheumatology (Oxford). 2019;58(11):1923-7. 
13. McWilliams DF, Marshall M, Jayakumar K, Doherty S, Doherty M, Zhang W, et al. Erosive and 
osteoarthritic structural progression in early rheumatoid arthritis. Rheumatology (Oxford). 
2016;55(8):1477-88. 
14. Higgins, JPT, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane Handbook for 
Systematic Reviews of Interventions version 6.1 2020. Available from: 
www.training.cochrane.org/handbook. 
15. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010 
rheumatoid arthritis classification criteria: an American College of Rheumatology/European League 
Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580-8. 
16. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical 
tutorial. Evidence-Based Mental Health. 2019;22:153-60. 
17. Schwarzer G. meta: An R package for meta-analysis. R News. 2007;7:40-5. 
18. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. J Statistical 
Software. 2010;36(3):1-48. 
19. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. 
BMJ. 2003;327(7414):557-60. 
20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, 
graphical test. BMJ. 1997;315(7109):629-34. 
21. Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Doing Meta-Analysis in R: A Hands-on Guide: 
bookdown.org/; 2019. Available from: 
https://bookdown.org/MathiasHarrer/Doing_Meta_Analysis_in_R/. 
22. Marwah RJ, Pickup ME, Al-Shakarchi H, Dixon JS, Lowe JR, Bird HA, et al. A pharmacological 
and clinical comparison of prednisolone and betamethasone in rheumatoid arthritis. Eur J Clin 
Pharmacol. 1982;23(4):321-5. 
23. Kirwan J, Hällgren R, Mielants H, Wollheim F, Bjorck E, Persson T, et al. A randomised 
placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis. Annals of 
the rheumatic diseases. 2004;63(6):688‐95. 
24. Buttgereit F, Strand V, Lee EB, Simon-Campos A, McCabe D, Genet A, et al. Fosdagrocorat 
(PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, 
multicentre, phase IIb study. RMD Open. 2019;5(1):e000889. 
25. Stock T, Fleishaker D, Wang X, Mukherjee A, Mebus C. Improved disease activity with 
fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with 
rheumatoid arthritis: a Phase 2 randomized study. International journal of rheumatic diseases. 
2017;20(8):960‐70. 
26. Di Munno O, Mazzantini M, Milani S, Pasero G. Clinical equivalence between deflazacort oral 
drops and tablets in active rheumatoid arthritis. Clin Rheumatol. 1999;18(2):140-4. 
27. Choy E, Kingsley G, Corkill M, Panayi G. Intramuscular methylprednisolone is superior to 
pulse oral methylprednisolone during the induction phase of chrysotherapy. British journal of 
rheumatology [Internet]. 1993; 32(8):[734‐9 pp.]. Available from: 
https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00095012/full. 
28. Smith M, Ahern M, Roberts-Thomson P. Pulse steroid therapy in rheumatoid arthritis: can 
equivalent doses of oral prednisolone give similar clinical results to intravenous 
methylprednisolone? Annals of the rheumatic diseases. 1988;47(1):28‐33. 
29. Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, et al. Efficacy 
of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints 
in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet (london, 
england). 2008;371(9608):205‐14. 
30. Alten R, Nolte M, Doring G, Werder K. Circadian versus ultradian glucocorticoid regimen in 
the treatment of rheumatoid arthritis. Aktuelle rheumatologie. 2009;34(6):363‐9. 
31. Arvidson N, Gudbjörnsson B, Larsson A, Hällgren R. The timing of glucocorticoid 
administration in rheumatoid arthritis. Annals of the rheumatic diseases. 1997;56(1):27‐31. 
32. Buttgereit F, Mehta D, Kirwan J, Szechinski J, Boers M, Alten RE, et al. Low-dose prednisone 
chronotherapy for rheumatoid arthritis: A randomised clinical trial (CAPRA-2). Annals of the 
Rheumatic Diseases. 2013;72(2):204-10. 
33. Alten R, Grahn A, Holt RJ, Rice P, Buttgereit F. Delayed-release prednisone improves fatigue 
and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in 
rheumatoid arthritis. RMD Open. 2015;1(1):e000134. 
34. Burmester GR, Buttgereit F, Bernasconi C, Álvaro-Gracia JM, Castro N, Dougados M, et al. 
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in 
rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. Lancet 
(london, england). 2020;396(10246):267‐76. 
35. Pincus T, Swearingen CJ, Luta G, Sokka T. Efficacy of prednisone 1-4 mg/day in patients with 
rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial. Annals 
of the Rheumatic Diseases. 2009;68(11):1715-20. 
36. Scott IC, Ibrahim F, Lewis CM, Scott DL, Strand V. Impact of intensive treatment and 
remission on health-related quality of life in early and established rheumatoid arthritis. RMD Open. 
2016;2(2):e000270. 
37. Van der Elst K, Verschueren P, Stouten V, Pazmino S, De Groef A, De Cock D, et al. Patient-
Reported Outcome Data From an Early Rheumatoid Arthritis Trial: Opportunities for Broadening the 
Scope of Treating to Target. Arthritis Care Res (Hoboken). 2019;71(12):1566-75. 
38. Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W. Minimal clinically important changes in 
chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain. 
2004;8(4):283-91. 
39. Clarke L, Kirwan J. Efficacy, safety and mechanism of action of modified-release prednisone 
in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2012;4(3):159-66. 
40. Gron KL, Ornbjerg LM, Hetland ML, Aslam F, Khan NA, Jacobs JW, et al. The association of 
fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with 
rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program. Clin Exp 
Rheumatol. 2014;32(6):869-77. 
41. Witt KA, Sandoval KE. Steroids and the blood-brain barrier: therapeutic implications. Adv 
Pharmacol. 2014;71:361-90. 
42. Burston JJ, Valdes AM, Woodhams SG, Mapp PI, Stocks J, Watson DJG, et al. The impact of 
anxiety on chronic musculoskeletal pain and the role of astrocyte activation. Pain. 2019;160(3):658-
69. 
43. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American 
College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis 
clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis 
Rheum. 1993;36(6):729-40. 
44. Wallace BI, Wallace DM, Waljee AK, Clauw DJ. Evidence to support or guide glucocorticoid 
tapering in rheumatoid arthritis is lacking. Ann Rheum Dis. 2019;78(12):1733-4. 
45. Bakker M, Jacobs J, Welsing P, Verstappen S, Tekstra J, Ton E, et al. Low-dose prednisone 
inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a 
randomized trial. Ann Intern Med. 2012;156(5):329‐39. 
46. Böhm C. On long term drug therapy of primary chronic polyarthritis. Die medizinische welt. 
1967;35:2047‐50. 
47. Schoger G. On the evaluation of the effect of a combination of salicylates and prednisolone 
in rheumatic diseases. Arzneimittel-forschung. 1968;18(6):758‐60. 
48. Corkill M, Kirkham B, Chikanza I, Gibson T, Panayi G. Intramuscular depot 
methylprednisolone induction of chrysotherapy in rheumatoid arthritis: a 24-week randomized 
controlled trial. British journal of rheumatology. 1990;29(4):274‐9. 
49. Kirwan J. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The 
Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. New England journal of 
medicine. 1995;333(3):142‐6. 
50. Montecucco C, Todoerti M, Sakellariou G, Scirè C, Caporali R. Low-dose oral prednisone 
improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-
month open-label randomised study. Arthritis research & therapy. 2012;14(3):R112. 
51. Matcham F, Norton S, Scott DL, Steer S, Hotopf M. Symptoms of depression and anxiety 
predict treatment response and long-term physical health outcomes in rheumatoid arthritis: 
secondary analysis of a randomized controlled trial. Rheumatology (Oxford). 2016;55(2):268-78. 
52. Choy E, Smith C, Farewell V, Walker D, Hassell A, Chau L, et al. Factorial randomised 
controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid 
arthritis. Annals of the rheumatic diseases. 2008;67(5):656‐63. 
53. Sheldon P. Ileum-targeted steroid therapy in rheumatoid arthritis: double-blind, placebo-
controlled trial of controlled-release budesonide. Rheumatology international. 2003;23(4):154‐8. 
54. van Gestel A, Laan R, Haagsma C, van de Putte L, van Riel P. Oral steroids as bridge therapy 
in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-
controlled trial. British journal of rheumatology. 1995;34(4):347‐51. 
55. Berry H, Huskisson EC. Isotopic indices as a measure of inflammation in rheumatoid arthritis. 
Ann Rheum Dis. 1974;33:523. 
56. Choy E, Kingsley G, Khoshaba B, Pipitone N, Scott D. A two year randomised controlled trial 
of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an 
incomplete response to disease modifying antirheumatic drugs. Annals of the rheumatic diseases. 
2005;64(9):1288‐93. 
57. Harris ED, Jr., Emkey RD, Nichols JE, Newberg A. Low dose prednisone therapy in rheumatoid 
arthritis: a double blind study. Journal of Rheumatology. 1983;10(5):713-21. 
58. Hua L, Du H, Ying M, Wu H, Fan J, Shi X. Efficacy and safety of low-dose glucocorticoids 
combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: 
a single-center, randomized, double-blind clinical trial. Medicine. 2020;99(27):e20824. 
59. Jasani MK, Downie WW, Samuels BM, Buchanan WW. Ibuprofen in rheumatoid arthritis 
clinical study of analgesic and anti-inflammatory activity. Ann Rheum Dis. 1968;27:457. 
60. Jelinek G, Will R, Dusci L, Potter J, Black K. Intravenous regional administration of 
methylprednisolone in rheumatoid arthritis. Rheumatology international. 1991;11(4‐5):147‐50. 
61. Kennedy A, Lee P, Webb J, Deodhar S. Evaluation of the effect and duration of triamcinolone 
acetonide in the treatment of rheumatoid arthritis. Current medical research and opinion. 
1973;1(4):212‐8. 
62. Lee P, Jasani MK, Dick WC, Buchanan WW. Evaluation of a functional index in rheumatoid 
arthritis. Scandinavian Journal of Rheumatology. 1973;2(2):71-7. 
63. Li L, Scudds R, Heck C, Harth M. The efficacy of dexamethasone iontophoresis for the 
treatment of rheumatoid arthritic knees: a pilot study. Arthritis care and research. 1996;9(2):126‐32. 
64. Pavelka K, Jr., Honzlova M, Vencovsky J. [Use of pulsed steroid therapy in active rheumatoid 
arthritis]. Cas Lek Cesk. 1992;131(19):593-9. 
65. Stenberg V, Fiechtner J, Rice J, Miller D, Johnson L. Endocrine control of inflammation: 
rheumatoid arthritis double-blind, crossover clinical trial. International journal of clinical 
pharmacology research. 1992;12(1):11‐8. 
66. Taylor W, Rajapakse C, Harris K, Harrison A, Corkill M. Inpatient treatment of rheumatoid 
arthritis with synacthen depot: a double blind placebo controlled trial with 6 month followup. 
Journal of rheumatology. 1999;26(12):2544‐50. 
67. van Everdingen  A, van Reesema S, Jacobs J, Bijlsma J. Low-dose glucocorticoids in early 
rheumatoid arthritis: discordant effects on bone mineral density and fractures? Clinical and 
experimental rheumatology. 2003;21(2):155‐60. 
68. van Everdingen A, van Reesema S, Jacobs J, Bijlsma J. The clinical effect of glucocorticoids in 
patients with rheumatoid arthritis may be masked by decreased use of additional therapies. Arthritis 
and rheumatism. 2004;51(2):233‐8. 
69. van Everdingen A, Jacobs J, Van Reesema S, Bijlsma J. Low-dose prednisone therapy for 
patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and 
side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 
2002;136(1):1‐12. 
70. Williams IA, Baylis EM, Shipley ME. A double-blind placebo-controlled trial of 
methylprednisolone pulse therapy in active rheumatoid disease. Lancet. 1982;2(8292):237-40. 
71. Dick W, Nuki G, Whaley K, Seodhar S, Buchanan WW. Some aspects in the quantitation of 
inflammation in joints of patients suffering from rheumatoid arthritis. Rheumatol Phys Med. 
1970;suppl 10:40-7. 
72. Kazkaz L. Methylprednisolone pulse therapy in the symptomatic relief of rheumatoid 
disease. Acta Therapeutica. 1990;16(4):329-35. 
73. Lee P, Baxter A, Dick W, Webb J. An assessment of grip strength measurement in 
rheumatoid arthritis. Scandinavian journal of rheumatology. 1974;3(1):17‐23. 
74. Liebling MR, Leib E, McLaughlin K, Blocka K, Furst DE, Nyman K, et al. Pulse 
methylprednisolone in rheumatoid arthritis. A double-blind cross-over trial. Ann Intern Med. 
1981;94(1):21-6. 
75. Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, et al. Effectiveness of 
methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other 
intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year 
results of CareRA, a randomised pragmatic open-label superiority trial. Annals of the Rheumatic 
Diseases. 2017;76(3):511-20. 
76. WANG Y-Y, LING B, Gulixian·Aierken, JI P, LUO L. Observation on the Effect of MTX or LEF 
Combined with Glucocorticoid in the Treatment of Elderly Patients with Rheumatoid Arthritis. 
Progress in Modern Biomedicine. 2017(15):2903-6. 
77. Fleischmann R, Furst DE, Connolly-Strong E, Liu J, Zhu J, Brasington R. Repository 
Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized 
Controlled Withdrawal Trial. Rheumatology and Therapy. 2020;7(2):327-44. 
78. Ferraz M, Visioni R, Oliveira L, Ciconelli R, Atra E. Intravenous methylprednisolone therapy in 
rheumatoid arthritis: a comparative dose study. Scandinavian journal of rheumatology. 
1992;21(5):260‐1. 
79. Vischer T, Sinniger M, Ott H, Gerster J. A randomized, double-blind trial comparing a pulse of 
1000 with 250 mg methylprednisolone in rheumatoid arthritis. Clin Rheumatol. 1986;5(3):325‐6. 
80. Fan PT, Yu DT, Clements PJ, Fowlston S, Eisman J, Bluestone R. Effect of corticosteroids on 
the human immune response: comparison of one and three daily 1 gm intravenous pulses of 
methylprednisolone. J Lab Clin Med. 1978;91(4):625-34. 
81. Iglehart I, Sutton J, Bender J, Shaw R, Ziminski C, Holt P, et al. Intravenous pulsed steroids in 
rheumatoid arthritis: a comparative dose study. Journal of rheumatology. 1990;17(2):159‐62. 
82. Radia M, Furst D. Comparison of three pulse methylprednisolone regimens in the treatment 
of rheumatoid arthritis. Journal of rheumatology. 1988;15(2):242‐6. 
83. Scudeletti M, Puppo F, Lanza L, Mantovani L, Bosco O, Iudice A, et al. Comparison of two 
glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated 
diseases. Eur J Clin Pharmacol. 1993;45 Suppl 1:S29‐34. 
84. Hayball PJ, Nation RL, Bochner F, Sansom LN, Ahern MJ, Smith MD. The influence of renal 
function on the enantioselective pharmacokinetics and pharmacodynamics of ketoprofen in patients 
with rheumatoid arthritis. Br J Clin Pharmacol. 1993;36(3):185-93. 
85. van der Veen MJ, Bijlsma JW. The effect of methylprednisolone pulse therapy on 
methotrexate treatment of rheumatoid arthritis. Clin Rheumatol. 1993;12(4):500-5. 
86. Kowanko IC, Pownall R, Knapp MS, Swannell AJ, Mahoney PG. Time of day of prednisolone 
administration in rheumatoid arthritis. Ann Rheum Dis. 1982;41(5):447-52. 
 
